Cell Biotech Introduces Pharmacy-Exclusive Newborn Probiotic‘DUOLAC Gold D-Drops’

Cell Biotech’s flagship probiotic brand DUOLAC, known for its robust and scientifically validated strains, has launched ‘DUOLAC Gold D-Drops,’ a pharmacy-exclusive probiotic designed specifically for newborns. The new product is a premium oil-based probiotic drop formulation that incorporates DUOLAC’s proprietary technology and uses only carefully selected strains that have been registered as GRAS by the U.S. FDA and validated through human clinical trials, ensuring a high level of safety.

The gut environment during the newborn stage plays a crucial role in immune system development. Newborns first acquire beneficial bacteria through the mother’s birth canal during natural delivery, and a healthy infant gut typically consists of approximately 70–90% Bifidobacterium. These bacteria help suppress harmful pathogens in the colon, enhance immune function, and play a key role in breaking down human milk oligosaccharides (HMOs) found in breast milk. However, with the increasing rate of cesarean deliveries, cases of Bifidobacterium deficiency in newborns have become more common, driving growing demand for newborn-specific probiotics, which are now widely regarded as an essential item for childbirth preparation.

In 2017, Cell Biotech became the first company in Korea to develop an oil-based probiotic drop for newborns with the launch of ‘DUOLAC Duo D-Drops,’ introducing a domestically produced alternative to a market previously dominated by imported products. Building on this legacy, ‘DUOLAC Gold D-Drops’ leverages the proven technology and trust of DUOLAC’s 30-year bestseller ‘DUOLAC Gold,’ delivering a high-potency, high-specification premium probiotic tailored for newborns.

Because probiotics involve the intake of live microorganisms, strain safety verification is paramount. ‘DUOLAC Gold D-Drops’ is formulated with four Bifidobacterium strains—CBT-BF3, CBT-BR3, CBT-BG7, and CBT-BT1—all of which have undergone Whole Genome Sequencing (WGS) and have been registered as GRAS by the U.S. FDA. The safety of these strains was further confirmed through a human clinical study conducted in collaboration with Ludwig Maximilian University of Munich, involving 106 newborns aged 0–12 months.

In addition, the four Bifidobacterium strains were shown to possess the ability to metabolize HMOs, which are essential for immune development and brain growth. The product features a high-dose formulation, delivering 2.8 billion CFU per serving with a guaranteed count of 1 billion CFU. It uses premium coconut-derived MCT oil and excludes silicon dioxide, artificial flavorings, and chemical emulsifiers. DUOLAC’s globally patented dual-coating technology is applied to 100% Korean-origin probiotic strains, ensuring high survivability and allowing for room-temperature storage. To enhance convenience, the product also contains 100% of the recommended daily intake of vitamin D (400 IU), an essential nutrient for newborn growth.

Meanwhile, ‘DUOLAC Gold D-Drops’ is positioned as a high-potency, high-specification product and is available exclusively through pharmacies, allowing newborn intake to be guided by professional pharmacist consultation.